February 4, 2021 – Hackensack, NJ – Researchers and clinical experts at Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network, were awarded Department of Defense funds to continue their work into convalescent plasma for treatment of COVID-19 patients.
The approximately $5.5 million will allow the researchers at Hackensack Meridian John Theurer Cancer Center at Hackensack University Medical Center, and their colleagues at the Hackensack Meridian Center for Discovery and Innovation (CDI) to continue phase 2 testing of the clinical treatments.
The goal of this outpatient work is to treat infected patients in the first 96 hours of symptoms with the antibodies found in plasma collected from COVID-19 survivors – with the aim to prevent hospitalization.
“We are trying to save lives,” said Michele Donato, M.D., FACP, CPE, chief of Stem Cell Transplantation and Cellular Therapy at John Theurer Cancer Center at Hackensack University Medical Center, and who is leading the study. “We believe we have done so – and the Department of Defense grant allows us to move the work forward to that end.”
The convalescent plasma program at Hackensack University Medical Center identifies “super donors” – those with the highest levels of neutralizing antibodies – through methodology developed by experts from the CDI. The new funding will support a study of early outpatient treatment with high-titer convalescent plasma for patients with at least one risk factor for severe disease.
Experts believe getting to these patients within the first four days of infection may make a significant difference in outcomes.
Convalescent plasma treatments have previously been used to fight other viral outbreaks, including those of severe acute respiratory syndrome (SARS), caused by a virus that’s a cousin to the one responsible for COVID-19, and which sickened thousands in 2002-2003.
What separates the Hackensack trial from most convalescent plasma trials across the nation is the use of plasma donors with higher levels of neutralizing antibodies.
The program in Hackensack was profiled early in the pandemic by major media outlets, including the TV newsmagazine 60 Minutes and The New York Times.
“The Department of Defense funds will further our efforts to establish the necessary standards for this to be used as successful therapy,” said David S. Perlin, Ph.D., the chief scientific officer and senior vice president of the CDI.
“Our researchers are always finding ways to accomplish their mission: to save and better lives,” said Ihor Sawczuk, M.D., FACS, president of Hackensack Meridian Health’s Northern Market, and the chief research officer of the network. “The federal grant in this case acknowledges their work and its promise.”
The views expressed in this article are those of the author and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.
ABOUT HACKENSACK MERIDIAN HEALTH
Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care.
Hackensack Meridian Health comprises 17 hospitals from Bergen to Ocean counties, which includes three academic medical centers – Hackensack University Medical Center in Hackensack, Jersey Shore University Medical Center in Neptune, JFK Medical Center in Edison; two children’s hospitals – Joseph M. Sanzari Children’s Hospital in Hackensack, K. Hovnanian Children’s Hospital in Neptune; nine community hospitals – Bayshore Medical Center in Holmdel, Mountainside Medical Center in Montclair, Ocean Medical Center in Brick, Palisades Medical Center in North Bergen, Pascack Valley Medical Center in Westwood, Raritan Bay Medical Center in Old Bridge, Raritan Bay Medical Center in Perth Amboy, Riverview Medical Center in Red Bank, and Southern Ocean Medical Center in Manahawkin; a behavioral health hospital – Carrier Clinic in Belle Mead; and two rehabilitation hospitals – JFK Johnson Rehabilitation Institute in Edison and Shore Rehabilitation Institute in Brick.
Additionally, the network has more than 500 patient care locations throughout the state which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, urgent care centers and physician practice locations. Hackensack Meridian Health has more than 36,000 team members, and over 7,000 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.
The network’s notable distinctions include having four hospitals among the top in New Jersey by U.S. News and World Report. Other honors include consistently achieving Magnet® recognition for nursing excellence from the American Nurses Credentialing Center and being named to Becker’s Healthcare’s “150 Top Places to Work in Healthcare/2019” list.
The Hackensack Meridian School of Medicine opened in 2018, the first private medical school in New Jersey in more than 50 years, welcomed its third class of students in 2020 to its On3 campus in Nutley and Clifton. Additionally, the network partnered with Memorial Sloan Kettering Cancer Center to find more cures for cancer faster while ensuring that patients have access to the highest quality, most individualized cancer care when and where they need it.
Hackensack Meridian Health is a member of AllSpire Health Partners, an interstate consortium of leading health systems, to focus on the sharing of best practices in clinical care and achieving efficiencies.
For additional information, please visit www.HackensackMeridianHealth.org.
